Amin S, LaValley M P, Simms R W, Felson D T
Boston University Arthritis Center, Massachusetts 02118, USA.
Arthritis Rheum. 1999 Aug;42(8):1740-51. doi: 10.1002/1529-0131(199908)42:8<1740::AID-ANR25>3.0.CO;2-E.
To determine if vitamin D is more effective than no therapy or calcium alone in the management of corticosteroid-induced osteoporosis, and to determine how vitamin D compares with other osteoporosis therapies, e.g., bisphosphonates, calcitonin, or fluoride, for this condition.
We evaluated all formulations of vitamin D, including its active metabolites and analogs. A systematic search for published and unpublished studies was conducted using MEDLINE (1966-December 1997), bibliographic references, abstracts from proceedings of recent national meetings, and contact with pharmaceutical companies and content experts. We included all randomized controlled trials lasting at least 6 months (and reporting extractable results), of patients receiving oral corticosteroids, that compared vitamin D with either 1) no therapy or calcium alone, or 2) bisphosphonates, calcitonin, or fluoride. The primary outcome measure of interest was change in lumbar spine bone mineral density.
We found a moderate beneficial effect of vitamin D plus calcium versus no therapy or calcium alone (9 trials) (effect size 0.60; 95% confidence interval [95% CI] 0.34, 0.85; P < 0.0001). In comparisons of vitamin D with other osteoporosis therapies, bisphosphonates were more effective than vitamin D (6 trials) (effect size 0.57; 95% CI 0.09, 1.05). Calcitonin was similar in efficacy to vitamin D (4 trials) (effect size 0.03; 95% CI -0.39, 0.45). Fluoride was more effective than vitamin D, but there were only 2 trials.
Vitamin D plus calcium is superior to no therapy or calcium alone in the management of corticosteroid-induced osteoporosis. Vitamin D is less effective than some osteoporosis therapies. Therefore, treatment with vitamin D plus calcium, as a minimum, should be recommended to patients receiving long-term corticosteroids.
确定维生素D在治疗糖皮质激素诱导的骨质疏松症方面是否比不治疗或单独使用钙更有效,并确定维生素D与其他骨质疏松症治疗方法(如双膦酸盐、降钙素或氟化物)相比在这种情况下的效果如何。
我们评估了维生素D的所有制剂,包括其活性代谢物和类似物。使用MEDLINE(1966年至1997年12月)、参考文献、近期全国会议论文摘要,并与制药公司和内容专家联系,对已发表和未发表的研究进行了系统检索。我们纳入了所有持续至少6个月(并报告可提取结果)的随机对照试验,试验对象为接受口服糖皮质激素的患者,这些试验将维生素D与以下两种情况进行了比较:1)不治疗或单独使用钙;2)双膦酸盐、降钙素或氟化物。主要关注的结局指标是腰椎骨密度的变化。
我们发现维生素D加钙与不治疗或单独使用钙相比有中度有益效果(9项试验)(效应大小0.60;95%置信区间[95%CI]0.34,0.85;P<0.0001)。在维生素D与其他骨质疏松症治疗方法的比较中,双膦酸盐比维生素D更有效(6项试验)(效应大小0.57;95%CI0.09,1.05)。降钙素的疗效与维生素D相似(4项试验)(效应大小0.03;95%CI -0.39,0.45)。氟化物比维生素D更有效,但仅有2项试验。
在治疗糖皮质激素诱导的骨质疏松症方面,维生素D加钙优于不治疗或单独使用钙。维生素D比某些骨质疏松症治疗方法效果差。因此,至少应建议接受长期糖皮质激素治疗的患者使用维生素D加钙进行治疗。